Brazil antitrust regulator, known as CADE, unanimously approved in a session broadcast online the purchase by Hypera of Buscopan drug line from Boehringer Ingelheim GmbH for 1.3 billion reais (US$252.5 million), reported Bloomberg.
Deal was approved on condition that Hypera divests from the products that compete with Buscopan.
Hypera, since the beginning of the operation, presented a proposal to sell its medicine Neocopan Composto to the company Uniao Quimica Farmaceutica Nacional to guarantee the approval of the deal.
Sale of Neocopan Composto has been carried out and approved by CADE previously.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.